2024-12-06 FDA Approves Zenocutuzumab in NSCLC/Pancreatic Cancer FDA Approves Zenocutuzumab in NSCLC/Pancreatic Cancer Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma. READ NOW 回上一頁
